Immungene

Partnering

Partnerships are an essential element of ImmunGene’s strategy to fully harness the commercial potential of its pipeline and proprietary technology platforms to develop effective therapies. ImmunGene is an ideal partner for pharmaceutical and biotechnology companies and academic institutions who are interested in next generation monoclonal antibody- based therapeutics for providing safe and effective treatment for a wide variety of diseases.

ImmunGene believes that collaborations are vital for both near term and long term value creation. We are actively looking for alliances with leading biotechnology and pharmaceutical companies by leveraging our robust platform technology as a tool to expand our capabilities to deliver breakthrough therapeutics to improve people's lives.

Technology Collaboration

ImmunGene has entered into a collaboration with Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) for its interferon payload technology to empower monoclonal antibodies. Cephalon Australia will apply ImmunGene's technology to their monoclonal antibodies to up to six of its new drug targets for cancers. Cephalon Australia will pay undisclosed fees including an up-front payment to ImmunGene for a four-year option to leverage ImmunGene's novel drug development technology in preclinical research on up to six of Cephalon Australia's drug candidates. Cephalon has the option to pay ImmunGene license fees for exclusivity on each of these candidates that it decides to move into clinical trials.

Cephalon Australia is responsible for research, clinical development, manufacturing and commercialization of products that result from the ImmunGene collaboration. ImmunGene is eligible to receive considerable payments for research, clinical and regulatory milestones for each drug candidate in the collaboration that is commercialized, in addition to royalties on worldwide net sales of any resulting products.

Collaboration Opportunities

We strive to work on collaborations that will provide us the opportunity to enhance our internal research and programs through exchange of technology and therapeutic programs. ImmunGene is also open to license its technology and developmental programs.

Companies interested in exploring partnering opportunities with ImmunGene or to learn about our technology should contact: bd@immunGene.com